最新ニュース DraftKings (NASDAQ:DKNG) 株価情報

DRAFTKINGS INC-CL A

DraftKings

DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in 28 states and iGaming in five states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.

Sports Betting

Sports

DKNG

バスケットボール界のレジェンド、レブロン・ジェームズ氏の息子であるBronny Jamesは、数年間で最も話題になるNBAの新人選手の1人だ。

レブロン・ジェームズ氏 カリフォルニア大学での試合で高得点

DraftKings Inc

Truist Securities analyst Matthew Coad initiates coverage on Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) with a Hold rating and announces Price Target of $11.

News

Price Target

Initiation

Analyst Ratings

LSPD

Truist Securities Initiates Coverage On Lightspeed Commerce with Hold Rating, Announces Price Target of $11

<ul>
<li>Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocol.</li>
<li>INB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.</li>
<li>Median PFS in patients receiving multiple doses of INB-200 exceeds the historical median overall survival (mOS) of 14.6 months with the SOC Stupp protocol; notably, four patients remain alive and progression free for a median of over two years &nbsp;</li>
</ul>

Biotech

Health Care

General

INAB

IN8Bio Announced New Long-term Clinical Data From Its Fully Enrolled Phase 1 Trial Of INB-200 In Patients With Newly Diagnosed Glioblastoma Multiforme, Demonstrating Prolonged Progression-Free Survival

<ul>
<li>ARO-ALK7 is the first investigational RNAi therapeutic to enter clinical studies that targets a gene expressed in adipose tissue</li>
<li>Study initiation highlights Arrowhead's leadership in the delivery of siRNA to multiple tissues and cell types throughout the body utilizing its proprietary and differentiated Targeted RNAi Molecule (TRiM&#x2122;) platform</li>
<li>In preclinical studies, ARO-ALK7 silenced Activin receptor-like kinase 7 (ALK7) expression in adipose tissue, which led to reduced body weight and fat mass with preservation of lean muscle</li>
</ul>
Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is designed to intervene in a known pathway that signals the body to store fat in adipose tissue. The study initiates in otherwise healthy obese subjects using single and multiple escalating doses of ARO-ALK7 monotherapy and is expected to progress rapidly to investigate combinations of ARO-ALK7 with tirzepatide in obese patients with and without type 2 diabetes.

ARWR

Arrowhead Pharma Doses First Subjects In Phase 1/2a Clinical Trial Of ARO-ALK7, Investigational RNAi Therapeutic Being Developed As Potential Treatment For Obesity

Shares of Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) rose sharply in <a href="https://www.benzinga.com/quote/BPMC/news">today's pre-market trading</a>.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced plans to acquire Blueprint Medicines for $9.5 billion.
Blueprint Medicines shares jumped 26.9% to $128.62 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares jumped 199% to $14.74 in pre-market trading after the company reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210 achieving statistically significant results for primary and key secondary endpoints in the treatment of Chronic Rhinosinusitis (CRS).</li>
<li>InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) rose 93.2% to $4.81 in pre-market trading.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) surged 69% to $32.02 in pre-market trading after the company said Atacicept ORIGIN Phase 3 trial met primary endpoint of reduction in UPCR for IgAN treatment.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) jumped 68.5% to $0.47 in pre-market trading after gaining 13% on Friday.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) surged 51.4% to $9.20 in pre-market trading after jumping 485% on Friday.</li>
<li>Black Spade Acquisition II Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSII#NASDAQ">BSII</a>) gained 37.3% to $13.29 in pre-market trading after falling 5% on Friday.</li>
<li>DigiAsia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) climbed 27.7% to $1.6990 in pre-market trading after jumping 24% on Friday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) rose 25.6% to $7.32 in pre-market trading.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) gained 14.1% to $109.32 in pre-market trading. BioNTech and Bristol Myers Squibb announced a global strategic partnership to co-develop and co-commercialize next-generation bispecific antibody candidate BNT327 broadly for multiple solid tumor types</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares dipped 23.2% to $3.77 in pre-market trading. ReShape Lifesciences entered into equity distribution agreement relating to sale of up to $9.7 million of shares of common stock.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 22.6% to $0.7500 in pre-market trading after the company announced suspension of Nasdaq trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) fell 20.2% to $0.8300 in pre-market trading after gaining 8% on Friday.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) declined 18.4% to $62.60 in pre-market trading after the company filed for mixed shelf offering.</li>
<li>ContextLogic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) shares tumbled 18.3% to $6.70 in pre-market trading. ContextLogic will commence trading on the OTC Markets and delist from the Nasdaq.</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) fell 17.9% to $0.8788 in pre-market trading after the company announced a proposed public offering.</li>
<li>Super League Enterprise, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) fell 16.4% to $0.1629 in today's pre-market trading. Super League Enterprise, on Friday, announced a registered direct offering.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) dipped 16% to $1.68 in pre-market trading. TIAN RUIXIANG shares gained 8% on Friday after the company announced plans to buy Ucare for $150 million in an all-stock deal.</li>
<li>Lucid Diagnostics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) shares fell 15.1% to $1.18 in pre-market trading. Lucid Diagnostics may offer sell shares of common stock of up to $25 MILLION.</li>
<li>Algoma Steel Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) fell 9.2% to $4.78 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45692676/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-8">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

ASTL

BMGL

BNAI

BNTX

BPMC

BSII

CLEU

FAAS

LOGC

LUCD

LYRA

RSLS

SBET

SLXN

TIRX

VERA

Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket

During a town hall in Butler County on Friday, Sen. Joni Ernst (R-Iowa) brushed off a voter's warning about the <a href="https://www.benzinga.com/25/05/45558613/house-advances-trumps-sweeping-one-big-beautiful-bill-after-key-medicaid-tax-and-border-security-changes">effects of losing healthcare</a> with a reminder about collective mortality, drawing widespread criticism.
What Happened: Ernst was questioned about President Donald Trump's "big, beautiful bill", which includes major cuts to welfare programs like Medicaid, according <a href="https://www.washingtonpost.com/politics/2025/06/01/joni-ernst-medicaid-comments/">to</a> The Washington Post.
When a participant warned that <a href="https://www.benzinga.com/general/health-care/25/05/45344596/house-republicans-push-880-billion-medicaid-cuts-to-renew-trump-tax-breaks-democrat-warns-millions-will-lose-their-health-care">people could die if Medicaid coverage was taken away</a>, Ernst replied, "Well, we all are going to die." "So, for heaven's sakes. For heaven's sakes, folks," she added.
On Saturday, Ernst posted a 24-hour Instagram Story video that seemed to make fun of the criticism she received for her comments.
Filming from a cemetery, she said, "I made an incorrect assumption that everyone in the auditorium understood that, yes, we are all going to perish from this earth." "So I apologize, and I'm really, really glad that I did not have to bring up the subject of the tooth fairy as well," she added, ending the vide with a religious message: "For those that would like to see eternal and everlasting life, I encourage you to embrace my Lord and savior Jesus Christ."
See Also: <a href="https://www.benzinga.com/news/retail-sales/25/06/45712543/us-tariff-impact-prices-surge-at-walmart-and-target-employees-say-some-jumps-top-38">US Tariff Impact: Prices Surge At Walmart And Target, Employees Say—Some Jumps Top 38%</a>
Why It Matters: The bill at the center of the controversy is projected by the Congressional Budget Office to withdraw Medicaid coverage from 8.7 million people and raise the number of uninsured Americans by 7.6 million over the next ten years.
In Iowa, where one in five residents depends on Medicaid, including half of all nursing home occupants, the damage could be severe.
Democrats were quick to respond to Ernst's statements. "Everybody in that audience knows that they're going to die. They would just rather die in old age, at 85 or 90, instead of dying at 40," said Sen. Chris Murphy (D-Conn.) on CNN. "When rural hospitals close because of this bill… more people will die at a younger age."
"Joni Ernst said the quiet part out loud," said DNC chairman Ken Martin in a statement. "They don't care whether their own constituents live or die as long as the richest few get richer."
Meanwhile, Office of Management and Budget Director Russell Vought <a href="https://www.benzinga.com/news/politics/25/06/45717492/medicaid-cut-concerns-are-totally-ridiculous-says-trumps-budget-chief-russell-vought-quips-i-love-e">dismissed fears about Medicaid cuts</a> as "ridiculous," and Speaker Mike Johnson (R-La.) argued that those who lose Medicaid <a href="https://benzinga.com/node/45716936">will do so by personal choice</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/financial-advisors/25/06/45712636/peter-lynch-we-are-not-saving-enough-money-thats-the-most-single-important-thing-people-have-to-do-they-have-to-save-some-more">Peter Lynch: &#8216;We Are Not Saving Enough Money, That&#8217;s The Most Single Important Thing People Have To Do, They Have To Save Some More&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Politics

Medicaid Cuts Backlash Grows As Sen. Joni Ernst Tells Voters 'Well, We All Are Going To Die,' Mocks Critics From A Cemetery

Sen. Elizabeth Warren (D-Mass.) expressed agreement with President Donald Trump on eliminating the federal debt ceiling while sharply criticizing proposed tax breaks for wealthy Americans amid escalating fiscal concerns.
What Happened: Warren shared a video of Trump&#8217;s remarks on her X account, stating: &#8220;Trump and I agree: the debt limit should be scrapped to prevent an economic catastrophe. Let&#8217;s pass a bipartisan bill and get rid of it forever. But jacking up the debt limit by $4 trillion to fund more tax breaks for billionaires is an outrage.&#8221;
In the video, Trump acknowledged Warren&#8217;s longstanding position, saying: &#8220;Elizabeth Warren and various other people would like to see that. Her whole career, she wanted to see it terminated, gotten rid of, not being voted on every five years or ten years. And the reason was because it&#8217;s so catastrophic for our country. And I always agreed with her.&#8221; 
Trump noted the debt ceiling&#8217;s automatic four-year extension in current legislation, calling potential defaults &#8220;too catastrophic.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">.<a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> and I agree: the debt limit should be scrapped to prevent an economic catastrophe. Let&#39;s pass a bipartisan bill and get rid of it forever. But jacking up the debt limit by $4 trillion to fund more tax breaks for billionaires is an outrage. <a href="https://t.co/tMRdSsY5St">pic.twitter.com/tMRdSsY5St</a>
&mdash; Elizabeth Warren (@SenWarren) <a href="https://twitter.com/SenWarren/status/1928540597180076252?ref_src=twsrc%5Etfw">May 30, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45716400/pharma-bro-martin-shkreli-sees-10-trillion-potential-in-palantir-but-cautions-one-bad-quarter-and-its-down-50">&#8216;Pharma Bro&#8217; Martin Shkreli Sees $10 Trillion Potential In Palantir, But Cautions: &#8216;One Bad Quarter And It&#8217;s Down 50%&#8217;</a>
Why It Matters: Trump&#8217;s debt ceiling support connects to his &#8220;One Big, Beautiful Bill,&#8221; which passed the House 215-214 but faces Senate resistance. The legislation uses a four-year debt ceiling extension to enable $3.8 trillion in additional deficit spending, according to <a href="https://www.benzinga.com/news/25/05/45634863/gop-senators-threaten-to-block-trumps-tax-and-spending-bill-over-deficit-medicaid-cuts-and-debt-ceil">Congressional Budget Office estimates</a>.
Warren agrees on eliminating the debt ceiling permanently but opposes the current $4 trillion increase for what she calls billionaire tax breaks. Republican senators <a href="https://www.benzinga.com/news/25/05/45634863/gop-senators-threaten-to-block-trumps-tax-and-spending-bill-over-deficit-medicaid-cuts-and-debt-ceil">threaten to block the bill</a> over deficit concerns.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45716383/trump-administration-shuts-down-66-million-food-stamp-fraud-and-bribery-scheme-arrests-usda-employee-and-5-others">Trump Administration Shuts Down $66 Million Food Stamp Fraud And Bribery Scheme, Arrests USDA Employee And 5 Others</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Regulations

Economics

Elizabeth Warren Agrees With Trump On Scrapping Debt Limit—But Blasts $4 Trillion Hike For Billionaire Tax Breaks

Truist Securities analyst Matthew Coad initiates coverage on Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy rating and announces Price Target of $58.

AFRM

Truist Securities Initiates Coverage On Affirm Holdings with Buy Rating, Announces Price Target of $58

KYMR

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

Truist Securities analyst Matthew Coad initiates coverage on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a Sell rating and announces Price Target of $68.

PYPL

Truist Securities Initiates Coverage On PayPal Holdings with Sell Rating, Announces Price Target of $68

Economist Lyn Alden warns that U.S. fiscal deficits are an unstoppable force, driving demand <a href="https://www.benzinga.com/25/05/45610847/bitcoins-setup-exact-same-like-golds-explosion-during-1970s-says-analyst-but-critics-have-something-to-add">for scarce assets</a> like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and gold.
What Happened: Speaking at Bitcoin conference 2025 last week, Alden popularized the phrase &#8220;nothing stops this train&#8221;—borrowed from the show Breaking Bad—to describe a fiscal trajectory that, in her view, is now governed by both mathematical inevitability and political intransigence.
"We're in a system where the brakes are gone," she <a href="https://www.youtube.com/watch?v=Giuzcd4oxIk">said</a>. "Raising interest rates only accelerates the federal deficit faster than it slows private borrowing."
Using historical data, Alden demonstrated how federal deficits used to rise during recessions and shrink during recoveries. 
That relationship broke down after 2017. Since then, unemployment has remained low while deficits have ballooned, reaching 6–7% of GDP outside of crisis periods.
"This is not just cyclical," she argued. "It's structural."
A major factor is demographics. 
As the Baby Boomer generation retires, Alden noted that Social Security's $3 trillion trust fund will be spent down, injecting more money into the economy while limiting political appetite for fiscal restraint. 
Also Read: <a href="https://www.benzinga.com/cannabis/25/05/45698521/bitcoin-drops-to-105000-after-trump-warns-hes-no-longer-mr-nice-guy">Bitcoin Drops To $105,000 After Trump Warns He&#8217;s &#8216;No Longer Mr. Nice Guy&#8217;</a>
"It's the third rail of U.S. politics," she said. "No party will touch it."
The result: long-term, unavoidable deficits that persist regardless of the business cycle or who wins elections.
Alden likened the system to a "shark that must keep swimming." 
Citing data from 110 years of debt history, she showed that total debt levels almost never decline. 
"The last time total U.S. debt dropped meaningfully was during the Great Depression and even in 2008, when it fell slightly, the Fed responded by ballooning the monetary base from $1 trillion to $6 trillion."
With U.S. debt now exceeding 100% of GDP and interest rates no longer structurally declining, Alden warned that interest expenses are consuming a rising share of federal outlays. 
"We're in Wonderland," she said. "The tools that worked for decades now operate in reverse."
What&#8217;s Next: In contrast to fiat's "flexible ledger," Alden positioned Bitcoin as a fundamentally different system: one based on absolute scarcity, transparency, and a fixed supply.
"The fiat system always falls back on printing more units," she said. "Bitcoin doesn't allow that."
Her conclusion: The only rational hedge against this unsustainable trajectory is to hold "the highest quality scarce assets, "chief among them, Bitcoin.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45697994/robinhood-ceo-says-political-infighting-is-a-concern-for-crypto-legislation">Robinhood CEO Says Political Infighting Is &#8216;A Concern&#8217; For Crypto Legislation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

'Nothing Stops This Train': US Fiscal Deficits Drive Bitcoin's Case As A Hedge, Says Lyn Alden

Truist Securities analyst Matthew Coad initiates coverage on Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Sell rating and announces Price Target of $31.

GLBE

Truist Securities Initiates Coverage On Global E Online with Sell Rating, Announces Price Target of $31

The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) affirms FY2025 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $2.98 analyst estimate..

Guidance

The Campbell's Affirms FY2025 Adj EPS Guidance of $2.95-$3.05 vs $2.98 Est

Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) ("Rivian") today announced that Rivian Holdings, LLC (the "Company"), Rivian, LLC ("Rivian LLC") and Rivian Automotive, LLC ("Rivian Automotive" and, together with the Company and Rivian LLC, the "Co-Issuers") intend to offer, subject to market and other customary conditions, $1,250,000,000 aggregate principal amount of senior secured green notes due 2031 (the "notes") in a private offering. Rivian expects to use the net proceeds from the offering of the notes, together with cash on hand, to redeem in full the $1,250,000,000 aggregate principal amount of the Co-Issuers' outstanding floating rate senior secured notes due 2026 (the "2026 Notes") and pay related fees and expenses. This press release does not constitute a notice of redemption with respect to the 2026 Notes.
The notes are expected to be guaranteed by each of the Company's subsidiaries that also guarantee the Co-Issuers' senior secured asset-based revolving credit facility (the "ABL Facility"). The notes and the guarantees are expected to be secured on a first-priority basis by substantially all assets of the Co-Issuers and the guarantors, other than ABL Priority Collateral (as defined below), if and when the previously announced loan facility with the Department of Energy is funded, on a first-priority basis by substantially all assets of Rivian New Horizon, LLC, and on a second-priority basis by the inventory, receivables, certain deposit accounts and certain related assets (which exclude intellectual property) which secure the ABL Facility on a first-priority basis (the "ABL Priority Collateral"), in each case subject to certain excluded assets and permitted liens.

RIVN

Rivian Automotive Intends To Offer $1.25B Senior Secured Green Notes Offering To Refinance Outstanding Senior Secured Notes due 2026

Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.66 by 10.61 percent. This is a 2.67 percent decrease over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $2.48 billion which beat the analyst consensus estimate of $2.43 billion by 1.83 percent. This is a 4.47 percent increase over sales of $2.37 billion the same period last year.

Earnings

Earnings Beats

Campbell Soup Q3 Adj. EPS $0.73 Beats $0.66 Estimate, Sales $2.48B Beat $2.43B Estimate

Truist Securities analyst Matthew Coad initiates coverage on Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Sell rating and announces Price Target of $60.

Truist Securities Initiates Coverage On Block with Sell Rating, Announces Price Target of $60

TradePulse Alert Confirms Early Up Move in LLY
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/30203153/Screenshot-2025-05-30-at-4.23.48%E2%80%AFPM-992x1024.png" alt="" class="wp-image-13683" /></figure>
Eli Lilly (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:24 AM on May 30th, a significant trading signal occurred for Eli Lilly (LLY) as it demonstrated a Power Inflow at a price of $734.98. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Lilly's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Lilly's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for LLY, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a> which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $734.98. The returns on the High price ($745.93) and Close price ($737.87) after the Power Inflow are respectively 1.5% and 0.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

WIIM

Technicals

Opinion

Signals

Trading Ideas

Eli Lilly Rises 1.5% After Key Trading Signal

Nokia and Andorix partner to accelerate Private 5G and Edge solutions in North American real estate market&nbsp;
<ul>
<li>Private 5G, Neutral Host Network and Edge Application OT solutions enabled by Nokia Digital Automation Cloud (DAC) to enable efficient building operations and improve tenant's satisfaction.&nbsp; &nbsp;</li>
</ul>

Nokia Teams Up With Andorix To Expand Indoor 5G and Edge Solutions Across U.S. And Canadian Properties

~ Alignment with FDA continues to support Accelerated Approval pathway ~
~ BLA submission planned for first quarter of 2026 ~
~ Conference call today at 8:30 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KJrUuvgpMd-Ddja3YfjTaW-sEFYSuEc8TNCL8DhDuaFHTkrvl5gSZYYVlr1J5ubOEYW0Znoht2JKxs4d8ldSNg==">uniQure</a> N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis plan and Chemistry, Manufacturing and Controls (CMC) information that will support a Biologics License Application (BLA) submission expected in the first quarter of 2026.
Statistical Analysis Plan
In the second quarter of 2025, the Company held a Type B meeting with the FDA to discuss the proposed use of external control data and the prospectively defined statistical analysis plan (SAP) in support of the planned BLA submission for AMT-130. The FDA continued to support its prior agreement that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval. The FDA agreed that the primary efficacy analysis for the BLA will evaluate the 3-year change in cUHDRS in high-dose AMT-130 patients compared to a propensity score-adjusted external control arm. The Company plans to use propensity score-weighted external control derived from the ENROLL-HD dataset for the primary analysis and to submit certain sensitivity analyses, including one using a propensity score-matched external control, as additional support.
The FDA also agreed that ENROLL-HD – a large, prospective, longitudinal, natural history study of patients with Huntington's disease – may be acceptable as the external control dataset for the primary analysis of the trial data along with additional sensitivity analyses using the TRACK-HD/TRACK-ON and PREDICT-HD datasets. To date, approximately 33,000 patients have enrolled in ENROLL-HD. Compared to previously used natural history studies like TRACK-HD and PREDICT-HD, ENROLL-HD offers a substantially larger sample size, lower attrition rates, and longer average patient follow-up. The Company expects the larger sample size to reduce variability in the external control data and enhance the robustness of the SAP.
The Company plans to submit an updated SAP consistent with discussions from the recently held Type B meeting to the FDA in the second quarter of 2025.
Chemistry, Manufacturing and Controls (CMC)
In the first quarter of 2025, the Company held a Type B meeting with the FDA to discuss CMC requirements in support of the planned BLA submission for AMT-130. The FDA agreed that validation of the AMT-130 manufacturing process should be possible using experience and prior knowledge from the etranacogene dezaparvovec-drlb (HEMGENIX&#xAE;) process, complemented with additional full-scale AMT-130 GMP batches and a single Process Performance Qualification (PPQ) batch.
The FDA also agreed with the Company's proposed drug product release testing plan, including the proposed potency assay, pending completion of qualification and specification setting activities.
Next Steps for the Planned BLA Submission
Based on these recent Type B meetings with the FDA, the Company continues to prepare for a BLA submission for AMT-130 in the treatment of Huntington's disease. Certain key next steps and expected timing include:
<ul>
<li>Q2 2025: submit updated SAP to the FDA &nbsp;</li>
<li>Q3 2025: initiate PPQ run and present topline Phase I/II data per the SAP &nbsp;</li>
<li>Q4 2025: hold pre-BLA meeting with the FDA &nbsp;</li>
<li>Q1 2026: submit BLA with a request for priority review designation &nbsp;</li>
</ul>

QURE

uniQure Secures FDA Alignment On AMT-130, Targeting 2026 BLA Submission

Asset Sales

Dow Announced That It Has Signed A Sale And Purchase Agreement To Sell Its 50% Interest In Dowaksa Advanced Composites Holdings Bv (Dowaksa) To Aksa Akrilik Kimya Sanayii A.Ş For Proceeds Of $125M

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), often dubbed China&#8217;s Tesla, announced its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45711427/nio-inc-provides-may-2025-delivery-update" rel="noreferrer noopener">May 2025 delivery results</a> on Monday.
NIO delivered 23,231 vehicles in May 2025, an increase of 13.1% year-over-year. The company&#8217;s newer brands, ONVO and FIREFLY, played a significant role in this growth.
The deliveries comprised 13,270 vehicles from the company&#8217;s premium smart electric vehicle brand NIO, 6,281 vehicles from the company&#8217;s family-oriented smart electric vehicle brand ONVO, and 3,680 vehicles from the company&#8217;s small smart high-end electric car brand FIREFLY.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45692725/alibaba-and-baidu-turn-to-chinese-ai-chips-as-us-sanctions-squeeze-nvidia-supply" rel="noreferrer noopener">Alibaba And Baidu Turn To Chinese AI Chips As US Sanctions Squeeze Nvidia Supply</a>
Year-to-date, NIO has delivered a total of 89,225 vehicles in 2025, marking a 34.7% increase year-over-year, the company said in a press release.
As of May 31, 2025, cumulative deliveries for the company have reached 760,789 vehicles.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) experienced a <a target="_blank" href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report" rel="noreferrer noopener">decline in sales</a> in China compared to rivals like&nbsp;NIO, Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>),&nbsp;Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and&nbsp;BYD Co., which posted strong growth in May.
NIO stock is down over 22% and 34% in the last 12 months. It grappled with&nbsp;challenges in achieving full-year profitability, primarily due to high research and development expenses and significant operational costs.
Trump administration&#8217;s tariff policies posed additional headwinds.
On May 12, Beijing and Washington <a href="https://www.benzinga.com/government/regulations/25/05/45676270/chinese-stocks-soar-as-us-court-blocks-trump-tariffs" target="_blank" rel="noreferrer noopener">agreed to lower tariffs</a> on each other&#8217;s products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China&#8217;s 125% duties on U.S. goods will drop to 10% for 90 days.
Price Actions: NIO stock is trading higher by 1.98% to $3.61 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45679204/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">Apple iPhone Shipment Could Decline In 2025 As Tariff, Competition Play Spoil Sport: IDC</a></li>
</ul>
Photo by Tada Images via Shutterstock

Asia

Movers

Tech

TSLA

XPEV

China's NIO Clocks 13% Deliveries Growth In May, Tesla Lags

Press Releases

DraftKings Announces Jason Robins' Participation in Upcoming Event

Entertainment

Arizona Winner Sets New Jackpocket Record, Wins $112 Million Mega Millions Jackpot From Ticket Ordered Using Jackpocket App

DraftKings to Release Fourth Quarter and Full Year 2024 Results on February 13, 2025 and Host Conference Call on February 14, 2025

DraftKings Reports Fourth Quarter and Fiscal Year 2024 Results

DraftKings Announces Launch of $500 Million Term Loan B Facility

Financing

DraftKings Announces Close of $600 Million Upsized Term Loan B Facility

DraftKings Renews State Council Funding Program and Expands Responsible Gaming Initiatives

DraftKings to Release First Quarter 2025 Results on May 8, 2025 and Host Conference Call on May 9, 2025

DraftKings Reports First Quarter Revenue of $1,409 Million

Accel Entertainment

PlayAGS

Ballys

Boyd Gaming

Codere Online Luxembourg, S.A. - Ordinary Shares

Codere Online Luxembourg

Churchill Downs, Incorporated - Common Stock

Churchill Downs

Century Casinos

Caesars Entertainment, Inc. - Common Stock

Caesars Entertainment

Everi Holdings

Full House Resorts

Golden Entertainment, Inc. - Common Stock

Golden Entertainment

Genius Sports

International Game Technology Ordinary Shares

Intl Game Tech

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment

Light & Wonder

Las Vegas Sands

Monarch Casino & Resort, Inc. - Common Stock

Monarch Casino & Resort

MGM Resorts International

Melco Resorts & Entertainment Limited - American Depositary Shares

Melco Resorts and Enter

Studio City International Holdings Limited American depositary shares, each representing four Class A ordinary shares

Studio City Intl Hldgs

PENN Entertainment

Red Rock Resorts, Inc. - Class A Common Stock

Red Rock Resorts

Rush Street Interactive, Inc. Class A Common Stock

Rush Street Interactive

Super Group (SGHC) Limited Ordinary Shares

Super Group (SGHC)

Wynn Resorts

Morgan Stanley

Susquehanna

Macquarie

Mizuho

Barclays

バスケットボール界のレジェンド、レブロン・ジェームズ氏の息子であるBronny Jamesは、数年間で最も話題になるNBAの新人選手の1人だ。
ロサンゼルス・レイカーズによって全体55番目の指名を受けた後、Jamesは2025年のNBAルーキー・オブ・ザ・イヤーを獲得する有力候補にはないが、賭け屋たちはそれをいまだに支持している。
出来事賭け屋たちは、ジェームズが2024年のNBAドラフトで全体1位指名される選手のうちの1人として賭けを入れ、<a href="https://www.benzinga.com/general/sports-betting/24/06/39513625/2024-nba-draft-no-clear-no-1-favorite-bronny-james-shakes-up-odds-people-are-always-intrig">その印を押した。</a>
カリフォルニア大学（USC）での25試合で、Bronnyは1試合平均19.4分、4.8得点、2.1アシスト、2.8リバウンドを記録した。
カレッジでの成績が、第1ラウンド指名の選手たちの数字ほどは目立っていないという事実にもかかわらず、伝説的なNBA選手の息子だというだけで、レイカーズ以外のチームもBronnyを指名しようとするだろう、と考える者もいた。一方で、父親のレブロンがフリーエージェンシーで契約を結ぶことが予想されていたレイカーズがBronnyを指名するだろうという意見もあった。
結局、レイカーズは2024年のNBAドラフトのセカンドラウンド全体55位でBronnyを指名した。チームはまた、レブロン・ジェームズと2年間の契約を再締結した。
現在のNBAルーキー・オブ・ザ・イヤーの賭け率は、ダフキングス社（NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>）のもので、Bronnyが+25000という率で賭けることができる。これは、Bronnyがルーキー・オブ・ザ・イヤーを獲得するための100ドルの賭けが、25000ドルの利益をもたらすということだ。
DraftKings社の現在の賭け率の内、優勢な選手は以下の通り（選手名、所属チーム、ドラフト全体順位）：
アレクサンドル・サー（ワシントン・ウィザーズ、2位）：+500
Zaccharie Risacher（アトランタ・ホークス、1位）：+650
ステフォン・キャッスル（サンアントニオ・スパーズ、4位）：+800
ザック・イーディ（メンフィス・グリズリーズ、9位）：+1,000
リード・シェパード（ヒューストン・ロケッツ、3位）：+1,000
ダルトン・クネヒト（ロサンゼルス・レイカーズ、17位）：+1,200
DraftKingsはまた、2024-2025シーズンにおけるBronnyの数々の賭けが可能なプロップベットも提供している。具体的には、1試合で15得点を記録するというもの（-110）、1試合で20得点を記録するというもの（+800）、1試合で25得点を記録するというもの（+1,800）、1試合で3本のスリーポイントを決めるというもの（+120）、1試合で10本以上のアシストを記録するというもの（+3,000）、そして何か1試合でダブルダブルを記録するというもの（+3,500）。
Bronny Jamesが新人王を獲得し、かつ父親のレブロンが2025年のNBA MVPを獲得するという賭けは、実際にはあり得ないかもしれない。レブロンはこれまでに4度MVPを受賞しており、2025年のMVP受賞のオッズは+20000として発表されている。
スポーツブックにはMVPおよび新人王を賭けることが可能であるが、これら2つの賭けを組み合わせようとしても、いくつかのスポーツブックでのテストでは許可されなかった。
レブロンがMVPを獲得し、Tyler Kolekが新人王を獲得するという賭けを組み合わせたものは、+20000のオッズが設定されている。この賭けはファンデュエル社では+4040000のオッズが設定されており、つまり1ドルの賭けが40400ドルの利益をもたらし、100ドルの賭けが400万ドルを超える利益をもたらすというわけだ。これが賭けが許可されていない理由なのだろう。
早い時期の賭けは、Bronnyが<a href="https://www.foxsports.com/stories/nba/2024-2025-nba-odds-bronny-james-most-bet-rookie-year">かなり支持されている</a>ことを示している。ルーキー・オブ・ザ・イヤーにとって最も悪いオッズを持っているにもかかわらず、BetMGM（MGMリゾーツ・インターナショナル（NYSE：<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>）とEntainのスポーツブック）では、33％の賭けがBronnyに集まっている。
本文のリンク： <a href="https://www.benzinga.com/general/sports-betting/24/07/39654951/nba-betting-odds-change-dramatically-after-free-agency-heres-the-publicly-traded-sports-te">NBAフリーエージェンシー後のNBA賭けの可能性が劇的に変わった</a>
この先どうなる歴史的に見て、第2ラウンド指名選手がルーキー・オブ・ザ・イヤーを獲得する確率は高くない。これまでに、ルーキー・オブ・ザ・イヤーを受賞した第2ラウンド指名選手はたった3人しかおらず（うち1人が2017年に受賞したマルコム・ブロッグダン氏（全体36位指名））、その他の2人は1960年代に受賞した。
この賞を受賞した最後の2人（ビクター・ウェンバーニャマ、パオロ・バンケロ）は全体1位指名された選手であり、1987-1988シーズン以降の受賞者のうち、1位指名外で受賞した選手は2人しかいない。
レイカーズがジェームズを指名することになり、そのことが他のチームに警告を促した可能性や、ジェームズを指名しようとした他のチームにとっての潜在的な利益については、多くのことが報じられた。Bronny JamesがNBAドラフトで失敗した選手としてラベリングされることを避けるためには、彼のプレイが話題を作り出す必要があるだろう。
レブロン・ジェームズ氏のNBAサマーリーグデビューでは、21分のプレイで4得点、2リバウンド、2アシストを記録した。フィールドゴールシュートでは9本中2本、スリーポイントシュートでは3本中0本を決めることができなかった。フリースローでは2本中0本を決めることができなかった。
レイカーズはサマーリーグの2試合とも敗戦し、Bronnyは膝の腫れのために2試合目に欠場した。
レイカーズの第1ラウンド指名選手であるダルトン・クネヒト氏は、レイカーズのサマーリーグの2試合とも12得点を挙げた。
次の一手
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/02/37239149/exclusive-draftkings-partnership-with-barstool-sports-getting-the-band-together-ceo-says-h">【独占】: DraftKings社とBarstool Sports社の提携、「バンドを揃えることになる」とCEO</a></li>
</ul>

Comments

DraftKings

ニュース

最新ニュース DraftKings (NASDAQ:DKNG) 株価情報

火曜日, 7 09, 2024

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル